Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A
Haemophilia · 2026-07 · 32 (4) · 974-981
DOI: 10.1111/hae.70284 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Haemophilia, online erschienen am 12.04.2026. Verfasst von Priyanka Raheja und 9 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia Centre, Barts Health NHS Trust, The Royal London Hospital, London, UK. Hauptthemen laut MEDLINE: Dependovirus, Genetic Therapy, Genetic Vectors, Hemophilia A. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BioMarin Pharmaceutical.
Abstract (Originalsprache)
Introduction
Valoctocogene roxaparvovec is an adeno‐associated virus vector serotype 5 (AAV5)‐mediated gene therapy for severe haemophilia A (HA).
Aim
Report the final safety and efficacy results of the phase 1/2 trial of valoctocogene roxaparvovec.
Methods
An open‐label phase 1/2 trial (NCT02576795) enrolled adult males with severe HA (factor VIII [FVIII] ≤1 IU/dL) without FVIII inhibitors, anti‐AAV5 antibodies, or liver dysfunction to receive 6 × 10 13 or 4 × 10 13 vg/kg valoctocogene roxaparvovec. Efficacy endpoints included FVIII activity (chromogenic), annualized bleeding rate (ABR) of treated bleeds, annualized FVIII infusion rate, and quality of life. Safety was assessed by adverse events (AEs). Year seven 6 × 10 13 vg/kg cohort results were reported previously.
Results
Five of six 4 × 10 13 vg/kg cohort participants completed the 7‐year study. Mean FVIII activity peaked within year 1 for the 4 × 10 13 cohort (week 52 FVIII, 21.1 IU/dL) and decreased to 4.2 IU/dL at the end of year 7. Across all follow‐up, mean ABR declined 87% from baseline to 1.6 bleeds/year and mean annualized FVIII use declined 93% to 10.3 infusions/year. Overall, 3/5 of the 4 × 10 13 participants remain off prophylaxis. Haemo‐QOL‐A Total Score was mostly stable from baseline. The last treatment‐related AE (TRAE) of alanine aminotransferase elevation occurred in year 1. No serious TRAEs occurred after year 1. No participants had thromboembolic events or developed FVIII inhibitors.
Conclusion
Over 7 years, valoctocogene roxaparvovec increased FVIII activity from baseline and improved haemostasis compared with FVIII prophylaxis for most participants. The 6 × 10 13 vg/kg dose was more efficacious than 4 × 10 13 vg/kg. No concerning long‐term safety signals were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haemophilia Centre, Barts Health NHS Trust, The Royal London Hospital, London, UK.
- Faculty of Medicine, University of Southampton, Southampton, UK.
- University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Independent Consultant, La Jolla, San Diego, California, USA.
- Haemophilia Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ORCID-Profile: Priyanka Raheja, Will Lester, Glenn F Pierce, Emily Symington
Förderung
- BioMarin Pharmaceutical
Zitieren
APA
Raheja, P., Rangarajan, S., Lester, W., Madan, B., Pierce, G. F., Symington, E., Millar, C., Osmond, D., Li, M., & Chavele, K. M. (2026). Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A. Haemophilia, 32(4), 974-981. https://doi.org/10.1111/hae.70284
Vancouver
Raheja P, Rangarajan S, Lester W, Madan B, Pierce GF, Symington E, et al. Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A. Haemophilia. 2026;32(4):974-981. doi:10.1111/hae.70284
BibTeX
@article{Raheja2026,
author = {Raheja, Priyanka and Rangarajan, Savita and Lester, Will and Madan, Bella and Pierce, Glenn F and Symington, Emily and Millar, Carolyn and Osmond, Dane and Li, Mingjin and Chavele, Konstantia-Maria},
title = {Final Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {4},
pages = {974--981},
doi = {10.1111/hae.70284}
}
EUVIMED